Advanced in Papular Mucinosis

Dr. Mark J. Fesler

Hematology Oncology | Transplant Surgery | Hematology
Van Amburg And Busiek Mds LLC
232 S Woods Mill Rd, Suite 330e, 
Chesterfield, MO 
Accepting New Patients
18 Years of Experience
Advanced in Papular Mucinosis
Van Amburg And Busiek Mds LLC
232 S Woods Mill Rd, Suite 330e, 
Chesterfield, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Mark Fesler is a Hematologist Oncology specialist and a Transplant Surgeon in Chesterfield, Missouri. Dr. Fesler has been practicing medicine for over 18 years and is rated as an Advanced provider by MediFind in the treatment of Papular Mucinosis. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Large-Cell Immunoblastic Lymphoma, and Bone Marrow Transplant. Dr. Fesler is currently accepting new patients.

His clinical research consists of co-authoring 18 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Papular Mucinosis.

Specialties
Hematology Oncology
Transplant Surgery
Hematology
Licenses
Internal Medicine in CO
Hospital Affiliations
St Lukes Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Home State Health
  • EPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

VAN AMBURG AND BUSIEK MDS LLC
232 S Woods Mill Rd, Suite 330e, Chesterfield, MO 63017

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Other, Procedure
Study Drugs: Carmustine, Cyclophosphamide, Cytarabine, Etoposide, Ibrutinib, Melphalan
Study Phase: Phase 3
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
A Randomized Phase III Trial of Consolidation With Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs Maintenance Rituximab Alone for Patients With Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2025
Intervention Type: Biological, Procedure
Study Drug: Rituximab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Drug, Other
Study Drugs: Brentuximab vedotin, Rituximab, Lenalidomide
Study Phase: Phase 3
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Enrollment Status: Terminated
Publish Date: October 13, 2023
Intervention Type: Drug
Study Drug: Brentuximab
Study Phase: Phase 2
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
A Randomized, Open Label, Phase 2 Study of Rituximab and Bendamustine With or Without Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Diffuse Large B-Cell Lymphoma
Enrollment Status: Terminated
Publish Date: October 16, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

18 Total Publications

Killing Two Birds With One Stone: Successful Management With Rituximab in the Coexistence of Myasthenia Gravis and Marginal Zone Lymphoma.
Killing Two Birds With One Stone: Successful Management With Rituximab in the Coexistence of Myasthenia Gravis and Marginal Zone Lymphoma.
Journal: Cureus
Published: September 23, 2023
Similar Doctors
Experienced in Papular Mucinosis
Dr. Sagun D. Goyal
Hematology Oncology | Hematology | Oncology
Experienced in Papular Mucinosis
Dr. Sagun D. Goyal
Hematology Oncology | Hematology | Oncology

Ssm Health Care Group

3635 Vista Ave, 
Saint Louis, MO 
 (14.5 miles away)
314-257-7400
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sagun Goyal is a Hematologist Oncology specialist and a Hematologist in Saint Louis, Missouri. Dr. Goyal is rated as an Advanced provider by MediFind in the treatment of Papular Mucinosis. Her top areas of expertise are Multiple Myeloma, Acute Myeloblastic Leukemia without Maturation, Acute Myeloblastic Leukemia with Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Goyal is currently accepting new patients.

Experienced in Papular Mucinosis
Dr. Manpreet K. Sandhu
Hematology Oncology | Hematology | Oncology
Experienced in Papular Mucinosis
Dr. Manpreet K. Sandhu
Hematology Oncology | Hematology | Oncology

Osf Multi-Specialty Group

2 Saint Anthonys Way, Suite 205, 
Alton, IL 
 (25.1 miles away)
618-462-2222
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Manpreet Sandhu is a Hematologist Oncology specialist and a Hematologist in Alton, Illinois. Dr. Sandhu is rated as a Distinguished provider by MediFind in the treatment of Papular Mucinosis. Her top areas of expertise are Plummer-Vinson Syndrome, Laryngeal Cancer, Childhood Iron Deficiency Anemia, and Lung Cancer. Dr. Sandhu is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Fesler's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 43 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile